Each session will last about 2.5 hours and start at 7 am PST. The presentations will cover applications of optical genome mapping (OGM) with Saphyr to analyze the genomes of patients with a variety of genetic diseases, blood cancers, solid tumors and repeat disorders as well as the studies supporting validation of clinical assays developed by Saphyr users. Real-time quotes, advanced visualizations, backtesting, and much more. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. For more information, visit www.bionanogenomics.com or www.lineagen.com. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. Should Investors Think Twice Before Running After BioNano Genomics? After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Bionanoâs Chief Medical Officer Alka Chaubey. Warrant (BNGOW) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. © 2021 GlobeNewswire, Inc. All Rights Reserved. I quickly realized that the research and clinical communities were not sufficiently aware of Saphyrâs capabilities as an informative tool for detecting structural variants of clinical significance. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of ⦠The event is being held virtually and concludes on January 15, 2021. Monday, January 11: Constitutional CytogeneticsThis session starts with a presentation on the clinical validation studies of Saphyr compared to the standard of care cytogenetics for constitutional genetic disease and prenatal testing. Alka Chaubey, FACMG, PhD, Chief Medical Officer of Bionano Genomics commented: âI joined Bionano Genomics in August of 2020 because I believed that Saphyr was finally ready to transform the way genomes are analyzed in cancer and genetic disease. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. The company plans to sell 33,333,350 shares of its common stock at a price of $6 per share, for an ⦠Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. After conclusion of the live event, the recordings will be made available for on-demand viewing. Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyrâs Utility in Genome Analysis for Genetic Disease and Cancer It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The stock closed Thursday at $5.00. As recently as Christmas, you could have picked some up ⦠Hear how Saphyrâs ultra-long DNA molecule imaging can measure repeat contractions causing FSHD, repeat expansions causing spinocerebellar ataxia and familial adult myoclonic epilepsy, and can potentially solve other genetic mysteries. Bionanoâs Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Join thousands of traders who make more informed decisions with our premium features. Bionano Genomics Announces Positive Outcome of Its Special Stockholder Meeting, Bionano Genomics Announces Continued Expansion of Global Business with Adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe and Australia, German Accreditation of Laboratory Developed Tests on Bionanos Saphyr System Accelerates Utilization in Clinical Diagnostics, BioNano Genomics Stock Is Dashing Towards a Brighter Future, Says Analyst, Bionano to Present at the September 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Bionano Data Provides Understanding of Repeat Expansion Disorders Causing Muscular Dystrophy and ALS, Bionano Genomics Continues to See Expansion in the Adoption of Saphyr for Digital Cytogenetics at Leading Medical Institutions, Bionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagens EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy, Bionano Genomics Announces Continued Expansion of European Business With Adoption of Saphyr at Three of Europes Largest Pediatric Hospitals in Spain, Italy and France, Vertebrate Genome Project Rules Bionano Optical Mapping Technology As Essential Part of Assembling Reference Quality Genomes, Bionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Independent Proxy Advisory Firm ISS Recommends Bionano Stockholders Vote FOR Authorized Shares Increase Proposal. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. We created this symposium as part of our efforts to change that. Important recent data will be presented at our symposium, which we believe demonstrates that Saphyr can detect all clinically reported structural variants identified by traditional cytogenetic methods, which short-read or long-read sequencing technologies have not been able to do. Each of these forward-looking statements involves risks and uncertainties. NEW YORK â Bionano Genomics on Wednesday priced a $200 million underwritten public offering of its common stock that it announced the previous day. Your browser is no longer supported. Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Best Stocks in the Past Week: Riot Blockchain, Microstrategy, 4 Top Stock Trades for Tuesday: MJ, NWL, CIIC, BNGO, Bionano Genomics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, Method for Solid Tumor Analysis with Saphyr Published by Penn State Institute for Personalized Medicine, Opening Largest Oncology Market to Optical Genome Mapping. Additional speakers show how Saphyr can find pathogenic variants undetected by traditional methods for a variety of genetic diseases and disorders of sex development.Tuesday, January 12: Heme MalignancyEight speakers from around the world will present results from their studies comparing Saphyr with the cytogenetic standard of care for genome analysis of a variety of heme malignancies including MDS, adult and pediatric B-ALL, and CLL leukemias, ending with the presentation of results from a large national multi-center evaluation on Acute Myeloid Leukemia.Wednesday, January 13: Solid TumorIn this session, speakers will discuss their analysis of solid tumor genome structure in head and neck cancer, non-inflammatory and inflammatory breast cancer, liver cancer, uveal melanoma, ending with an update on the development of a cancer LDT with Saphyr.Thursday, January 14: Complex Molecular DiagnosticsThis session returns to genetic diseases with a focus on repeat expansions and contractions and other complex molecular mechanisms. Analyst Weighs In, Bionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares, Bionano Genomics' stock rally result of awareness push in 2019 and 2020 about its genomic technology: analyst, UPDATE: Bionano Genomics prices $200 million underwritten stock offering at a discount of $6 a share, Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock, Bionano Genomics to sell more shares, stock falls, Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock, MD Anderson Cancer Center Publication Shows How Bionanos Saphyr System Can Significantly Reduce Time to Actionable Results for Myelodysplastic Syndrome Patients, Day Five of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness, Day Four of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Solves Genetic Mysteries, Enables Study of Complex Genetic Diseases, Simplifies Muscular Dystrophy Testing, Day Three of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Provides Complete Structural Variation Analysis in Solid Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets, Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement, Day Two of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Outperforms Standard Cytogenetics in Heme Malignancies, is Less Expensive, Provides Actionable Information Faster, in Single Assay, Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares, Day One of Bionanos Next-Generation Cytogenomics Symposium: Customer Progress in Applications Development in Prenatal Testing, Validation Against Traditional Cytogenetics and Resolution for Undiagnosed Patients, COVID-19 Host Genome SV Consortium Identifies Structural Variants with Possible Roles in Pathogenesis and Outcomes in Severely Ill COVID-19 Patients Using Bionanos Saphyr® System, Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyrs Utility in Genome Analysis for Genetic Disease and Cancer, Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share, Bionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock, Bionano Genomics shares fall after plan to sell more stock, The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data, Why Bionano Genomics Stock Skyrocketed More Than 100% Today, Return On Capital Employed Overview: Bionano Genomics, Bionano Genomics Publishes Study on Autism Risk Genes After Detailed Analysis of The Genome of Professor Temple Grandin, Who Has Brought Awareness to Autism Spectrum Disorder Through Her Activism, Bionanos Genome Mapping Platform Could Be a Game Changer, Says Analyst, Bionano Genomics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule, Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that Uses Whole Genome Analysis with Saphyr as Alternative to Chromosomal Microarray and Karyotyping, BioNano Genomics: Set to Execute in 2021, Says Analyst, Publication Reveals in Side-by-Side Comparison that Method Using PacBio Sequencing Detects Only 72% of the Large Structural Variants Detected by Optical Genome Mapping with Saphyr, Bionano Genomics Achieves Key Milestone with Software Update for its Saphyr System that Increases Throughput to 96 Human Genomes Per Week and Adds Saphyr Assure for Monitoring System Health, Bionanos Saphyr System Used to Characterize Virus Integration Into Human Genome, Bionano Genomics Users Present the Saphyr System As a Novel Diagnostic Tool for Hematological Malignancies at ASH 2020, Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020, Is Now the Time to Pull the Trigger on Bionano Stock? Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021, Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options, Why Bionano Genomics (BNGO) Might Surprise This Earnings Season, Bionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr, Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference, Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know, Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer, Bionanos Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed, Analyst Pounds the Table on Bionano (BNGO) Stock, Analyzing Bionano Genomics's Unusual Options Activity. Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. âFriday, January 15: Covid-19 Host Genome SV Expert Panel SessionKey members of the COVID-19 Host Genome SV Consortium will present how they are using Saphyr and other genomics technologies to detect structural variants in the human genome that can predispose to mild or severe COVID-19 disease. Did The Underlying Business Drive Bionano Genomics' (NASDAQ:BNGO) Lovely 997% Share Price Gain? We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com, Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com, Media Contact:Darren Opland, PhDLifeSci Communications+1 (617) 733-7668darren@lifescicomms.comÂ. On top of that, itâs evident that Bionano Genomics is a true innovator with a groundbreaking medical tech platform. Bionano Genomics, Inc. (BNGO) closed at $11.85 in the latest trading session, marking a -1.41% move from the prior day. These Analysts Say Yes, Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update, Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionanos Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients, Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionanos Optical Genome Mapping Technology Can Diagnose Significantly More Patients Than Standard of Care Methods Alone, Prowess of Bionano Genomics Saphyr System in Uncovering Novel Genetic Variations That Cause Cancer and Genetic Disease in Full Display at ASHG 2020, Rockefeller University Scientist Uses Bionano Saphyr to Analyze Genomes of Patients and Animals Susceptible to COVID-19, Bionano Genomics Releases Major Update to Its Suite of Software Tools That Simplifies Clinical Analysis, Reduces Time to Actionable Results and Makes Adoption by Clinical Labs Easier, Bionano Genomics' Saphyr System Shown to be Indispensable for the Analysis of Certain Genetic Disease Causing Variants, Bionano Genomics to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 12, Bionano's Saphyr Plays Essential Role in Identifying Three Previously Unknown Genetic Mutation Types in Cancer in Study from Weill Cornell, Boston Childrens Hospital Is Using Bionanos Saphyr To Study Children With Severe COVID-19 Disease. BioNano Genomics (NASDAQ: BNGO) went public in August 2018, selling 3.4 million shares of BNGO stock. Speakers will present on their study of 37 critically ill, ICU-admitted patients, on children with MIS-C, on comparative genomics of SARS-CoV-2 infection susceptible animals and people, and more. We are excited to show the global community how Saphyr enables next-generation cytogenomics.â. The full schedule of speakers and registration access is available at http://bit.ly/3pLPT28. Bionano Genomics Inc. BNGO, -12.68% said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. I believe this event will be a turning point for Bionano Genomics as we demonstrate the remarkable capabilities of OGM with Saphyr and how it has the potential to become a standard platform in the pathologistâs and researcherâs armamentarium.â, Erik Holmlin, PhD, CEO of Bionano Genomics commented: âOver the last year weâve made tremendous progress in advancing the capabilities of Saphyr to detect the various classes of large genomic variants that are relevant in cancer and genetic disease with high throughput and low cost in a simple workflow. MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Bionano Genomics, Inc. (BNGO) Upgraded to Buy: What Does It Mean for the Stock? Bionano Genomics, Inc. (BNGO) Gains As Market Dips: What You Should Know, Largest Hospital Diagnostic Lab in Canada Pilots Bionanos Saphyr; Seeking to Convert 30-Year-Old Workflow Based on Multiple Technologies Into a Single, High-Resolution Assay to Transform Cancer Diagnosis, Bionano Stock Gets a New Street-High Price Target, 3 Stocks That Turned $200,000 Into $1 Million (or More) in 3 Months, Presentation Recordings from Bionanos Next-Generation Cytogenomics Symposium, its Most Attended Event to Date, Now Available Online, Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know, Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research, Dr. Gordana Raca from Childrens Hospital Los Angeles Presents Findings That Show Saphyr Detects Druggable Gene Fusions in Pediatric Acute Leukemias that NGS and Cytogenetics Missed, Bionano Chief Medical Officer Presents Vision for Optical Genome Mapping as a First Line Clinical Tool for Cancer and Genetic Disease Testing at Festival of Genomics & Biodata, Bionano Significantly Reduces Analysis Cost and Time to Actionable Results with Update to its Cloud Compute, 3 Electric Stocks That Turned $100,000 Into $1 Million in 6 Months, Why Bionano Genomics Stock Rocketed More Than 28% Today, Is Bionano Stock Still Worth Buying After Its 2,300%-Plus Rally? Bionano Genomics' stock rally result of awareness push in 2019 and 2020 about its genomic technology: analyst Published: Jan. 22, 2021 at 9:47 a.m. SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the kick-off its 5-day Next-Generation Cytogenomics Symposium, which starts Monday January 11 and will feature 33 presentations by distinguished Saphyr users from leading hospitals and medical research institutions around the world. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionanoâs technology in basic genetic research and clinical settings, and in the contexts and applications contemplated by the presentations identified in this press release; adoption of Saphyr as a standard platform in research and pathology settings; and the execution of Bionanoâs strategy.